Physician profile
Jack E Belen
NPI 1093792053
$491.29
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.79 · 2020: $47.60 · 2021: $179 · 2022: $211.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.75 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $115.16 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $83.77 | 2021-2022 | |
| Genzyme Corporation | $49.23 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.23 | 2022 | |
| Covis Pharma Gmbh | $20.66 | 2022 | |
| Insmed, INC. | $19.83 | 2021 | |
| Philips North America LLC | $17.66 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Belen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.